

# Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.  
Senior Vice President  
Head of Lifecycle Management Marketing Unit  
Tatsuro Kosaka

February 4/5, 2009

# Forward Looking Statements

---

This presentation may include forward looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

# Projects under Development (as of February 2009)

	Phase I	Phase II	Phase III	Filed
Oncology	<i>R1273 (BC)</i> <u>TP300 (CRC)</u> <u>CIF (solid tumor)</u> <u>GC33 (LC)</u> <i>R7159 (NHL)</i> <u>CKI27 (solid tumor)</u> <i>R1507 (solid tumor)</i>	<u>Actemra (multiple myeloma)</u> <i>Avastin (BC)</i> <i>Tarceva (PC)</i> <i>R744 (Mircera CIA)</i>	Epogin (CIA) <i>Avastin (Adj. CC)#</i> <i>Avastin (GC)#</i> <i>Avastin (Adj. BC)#</i> <i>Herceptin (GC)#</i> <i>Xeloda (GC)</i>	<i>Xeloda (CRC/ combo)</i> <i>Avastin (NSCLC)</i>
Bone & Joint		<i>R484</i> <i>(Bonviva oral osteoporosis)</i> <u>Actemra (RA:S.C.)</u>	<i>R484 (Bonviva iv osteoporosis)</i> ED-71 (osteoporosis) <u>Actemra (sJIA)</u> <i>R1594 (RA) #</i>	<u>Actemra (RA)</u>
Renal			<i>R744</i> <i>(Mircera renal anemia)</i>	
Transplant, Immunology Infection	<u>Actemra (SLE)</u> <u>Actemra</u> <i>(castleman's disease)</i> <u>NA808 (chronic hepatitis C)</u>	Actemra <i>(crohn's disease)</i>	<i>Pegasys / Copegus (liver cirrhosis)</i> <i>Pegasys (chronic hepatitis B)</i>	
Others	<i>R1583 (type II diabetes)</i> <i>R1579 (type II diabetes)</i> *GM-611 <i>(diabetic gastroparesis)</i> <u>CSG452 (type II diabetes)</u>	<i>R1678 (schizophrenia) #</i> <u>*GM-611 (IBS)</u> <u>*GM-611 (diabetic gastroparesis)</u>		Epogin <i>(autologous transfusion)</i>

\*GM-611 is being considered for out-licensing

(Italics: Roche projects, Underlined: overseas' clinical development, #: participation in multi-national studies)


## Major Topics (October 2008 ~ February 2008)

---

- MRA (RoActemra in EU, Actemra outside of EU):
  - Approved for rheumatoid arthritis by EMEA
  - In US, Roche is planning to resubmit the Complete Response to the FDA in the third quarter of 2009, completing the REMS plan and additional pre-clinical studies
  - Started phase I / II study for subcutaneous injection formulation for rheumatoid arthritis in Japan and overseas
- Oxarol: Approved for additional indication of palmoplantar pustulosis
- R435 (Avastin): Filed for additional indication of non-small cell lung cancer and received priority review designation
- ED-71: Phase III clinical trials met primary endpoint in osteoporosis
- CKI27 (R7304): Roche started overseas Phase I for solid tumors (A compound licensed-out to Roche)
- R1507: Started Phase I for solid tumors

# Projected Submissions

Filings planned each year



## Contacts:

### Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607

e-mail: [pr@chugai-pharm.co.jp](mailto:pr@chugai-pharm.co.jp)

Masayuki Yamada, Seiji Shimada, Hiroshi Araki

### Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607

e-mail: [ir@chugai-pharm.co.jp](mailto:ir@chugai-pharm.co.jp)

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita